10-Q: Healthy Extracts Inc. Reports Improved Revenue and Reduced Losses in Q2 2024

Healthy Extracts Inc. saw a significant increase in revenue and a reduction in net losses for the second quarter of 2024 compared to the same period last year.

Summary

• Healthy Extracts Inc. reported a revenue of $1,597,175 for the six months ending June 30, 2024, compared to $1,203,427 for the same period in 2023.
• The company's cost of revenue increased to $702,728 for the six months ending June 30, 2024, up from $640,517 in 2023.
• Operating expenses decreased significantly to $968,427 for the six months ending June 30, 2024, compared to $2,223,972 in 2023.
• The net loss for the six months ending June 30, 2024, was $(747,758), a significant improvement from the $(1,846,392) loss in the same period of 2023.
• The company's cash balance increased to $148,231 as of June 30, 2024, from $19,441 at the end of 2023.
• The company has a going concern warning due to accumulated losses of $19,149,075 since inception and will need to raise capital to continue operations.

Sentiment

Score: 6

Explanation: The document shows positive trends in revenue growth and reduced losses, but the going concern warning and reliance on external funding temper the overall sentiment. The company is making progress but still faces significant financial challenges.

Positives

• The company experienced a significant increase in revenue, indicating strong sales growth.
• Operating expenses were substantially reduced, leading to improved profitability.
• The net loss was significantly reduced, showing progress towards financial stability.
• The company's cash position improved, providing more financial flexibility.
• Gross profit increased substantially, reflecting better cost management and pricing strategies.
• Cost of revenue as a percentage of revenues decreased, indicating improved efficiency.

Negatives

• The company still reported a net loss for the period, indicating ongoing financial challenges.
• The company has a going concern warning due to accumulated losses and will need to raise capital to continue operations.
• The company has a history of losses and has relied on debt and equity financing to sustain operations.
• The company's disclosure controls and procedures were not effective at the reasonable assurance level due to material weaknesses.

Risks

• The company has a going concern warning, indicating a risk of not being able to continue operations without additional funding.
• The company's ability to repay its obligations depends on raising significant capital from other sources.
• The company's disclosure controls and procedures were not effective at the reasonable assurance level due to material weaknesses.
• The company's future success depends on its ability to generate more revenue and manage its expenses effectively.
• The company's products have not been evaluated by the FDA or any similar regulatory body for safety and efficacy.

Future Outlook

The company expects strong revenue growth to continue as its direct consumer sales and marketing efforts continue to perform. The company anticipates that its cash needs will be satisfied through increased revenues and the issuance of debt or the sale of its securities until such time as its cash flows from operations will satisfy its cash flow needs.

Management Comments

• Management plans to keep seeking funding through debt and equity financing which are intended to mitigate the conditions that have raise substantial doubt about the entitys ability to continue as a going concern.
• Management believes that based upon qualitative factors, no impairment of indefinite-lived intangible assets is necessary.
• Management has provided for any risks in the current inventory allowance booked.

Industry Context

The company operates in the nutraceuticals market, which is a high-growth sector. The company's focus on heart, brain, and immune health aligns with current consumer trends. The company's products are plant-based, which is also a growing trend in the health and wellness industry.

Comparison to Industry Standards

• The company's revenue growth of 33% for the six months ended June 30, 2024, is a positive sign compared to the industry average, but it is important to compare this to specific competitors in the nutraceutical space.
• The reduction in operating expenses by 56% is a significant improvement and suggests better cost management compared to industry benchmarks.
• The company's net loss of $(747,758) for the six months ended June 30, 2024, is still a loss, but it is a substantial improvement compared to the $(1,846,392) loss in the same period of 2023, indicating progress towards profitability.
• The company's cash balance of $148,231 as of June 30, 2024, is relatively low compared to larger players in the industry, highlighting the need for additional funding.
• The company's reliance on debt and equity financing is common for early-stage companies in the nutraceutical industry, but it also indicates a higher risk profile compared to established companies with strong cash flows.
• The company's gross profit margin of 56% for the six months ended June 30, 2024, is a positive sign and is in line with industry standards for nutraceutical companies.

Related Party Transactions

• The company had expenses totaling $0 to an officer and director for salaries for the three months ended June 30, 2024.
• The company has related party notes payable outstanding.

Stakeholder Impact

• Shareholders may be concerned about the going concern warning and the need for additional funding.
• Employees may be affected by the company's financial challenges and the need to improve performance.
• Customers may be impacted by any changes in the company's operations or product offerings.
• Suppliers may be affected by the company's ability to pay its obligations.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company will continue to focus on increasing revenue through direct consumer sales and marketing efforts.
• The company will seek additional funding through debt and equity financing.
• The company will continue to monitor and manage its operating expenses.
• The company will continue to evaluate its inventory and make adjustments as needed.

Key Dates

Keywords

nutraceuticals, revenue, net loss, operating expenses, financial results, going concern, debt, equity, cash flow, financial statements